Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Y16
Cat. No.:
OB0225LY-0078
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Y16 is a specific inhibitor of LARG and G protein-coupled Rho GEFs that inhibits LARG-RhoA interaction.
Synonym:
429653-73-6; (E)-4-(3-((3-Methylbenzyl)oxy)benzylidene)-1-phenylpyrazolidine-3,5-dione; 4-(3-((3-Methylbenzyl)oxy)benzylidene)-1-phenylpyrazolidine-3,5-dione; (4E)-4-[[3-[(3-Methylphenyl)methoxy]phenyl]methylidene]-1-phenylpyrazolidine-3,5-dione; 4-[1-[3-(3-Methyl-benzyloxy)-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione; (4E)-5-Hydroxy-4-{3-[(3-methylbenzyl)oxy]benzylidene}-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
CAS No.:
429653-73-6
Compound CID:
989521
Formula:
C24H20N2O3
Formula Weight:
384.43
Specification
Relative Density:
1.273 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Y16 can be used for novel inhibitor screening and cancer research.
Library Information
Targets:
GTPase superfamily
Receptors:
Ras; Rho GEFs
Pathways:
Cell cycle/Checkpoint; MAPK; GPCR/G protein
Plate Number:
AOCL-1
Plate Location:
h11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
10 mg/mL; 26.01 mM
